Propranolol is Not Indicated for Vestibular Dizziness
There is no established evidence-based dosing regimen for propranolol in the treatment of vestibular dizziness, as this is not a recognized indication for the medication. The provided evidence contains no guidelines or research supporting propranolol use specifically for "vestibular dizziness" as a diagnostic entity.
Critical Distinction: Vestibular Migraine vs. Vestibular Dizziness
The question conflates two different conditions:
- Vestibular migraine is a specific neurological disorder with episodic vertigo in migraine patients, for which propranolol has emerging evidence
- Vestibular dizziness is a non-specific symptom that could represent multiple etiologies (BPPV, vestibular neuritis, Ménière's disease, etc.)
If the Question Refers to Vestibular Migraine
For vestibular migraine prophylaxis, propranolol is typically dosed at 80-160 mg once daily using extended-release formulations, or divided into 2-3 times daily for immediate-release preparations 1. The evidence shows:
- Starting dose: 80 mg once daily (extended-release) 2
- Maintenance dose: 160-240 mg once daily for migraine prophylaxis 2
- Dosing frequency: Once daily for extended-release; 2-3 times daily for immediate-release formulations
- Titration: Increase gradually at 3-7 day intervals until optimal response 2
Recent systematic review data (2025) identifies propranolol as a first-line prophylactic agent for vestibular migraine, with moderate-quality evidence supporting its efficacy in reducing vertigo frequency and severity 1. However, the specific dosing protocols varied across studies, and no standardized regimen exists specifically for vestibular migraine versus traditional migraine prophylaxis.
Common Pitfalls to Avoid
Do not use propranolol for acute vestibular symptoms - It is a prophylactic agent requiring weeks to achieve therapeutic effect 2
Screen for contraindications before prescribing: asthma, heart block, decompensated heart failure, bradycardia 2
Monitor for adverse effects: hypotension, bradycardia, fatigue, sleep disturbances, and potential worsening of depression 2
Counsel patients about timing: Extended-release formulations provide 24-hour coverage with once-daily dosing; immediate-release requires multiple daily doses for sustained effect 3
Assess response at 4-6 weeks - If no improvement after reaching maximum tolerated dose, discontinue and consider alternative prophylaxis 2
Alternative Considerations
If the patient has benign paroxysmal positional vertigo (BPPV), propranolol is inappropriate - canalith repositioning maneuvers are first-line treatment 4. For Ménière's disease, betahistine or diuretics are preferred over beta-blockers 5. For vestibular neuritis, acute management focuses on vestibular suppressants (not propranolol) followed by vestibular rehabilitation 4.
The critical first step is accurate diagnosis of the underlying vestibular disorder before initiating any pharmacologic prophylaxis.